



National Association of State
Controlled Substances Authorities



NASCSA NEWS

August 20, 2014

Contact Us

NASCSA
72 Brook Street
Quincy, MA 02170
Phone: (617) 472-0520
Fax: (617)472-0521
E-mail:
kathykeough@nascsa.org
Website: www.nascsa.org
Webmaster: ward@nascsa.org

NASCSA's State Profiles Updated

One of NASCSA's most important products to date has been the maintenance of its "[State Profiles](#)" that has helped state members and others with a variety of information specific to each state including state controlled substances authority contacts, relevant statutes and rules, as well as important information related to state Prescription Monitoring Program contacts and applicable regulations.

This spring the Survey/Data Committee, with authorization by the Executive Committee hired Bonnie Barnard, formerly with Walgreens and the Indiana State Police, as well as a former board member of NASCSA to conduct a comprehensive update of these profiles. We appreciate the quick response from our

Save the Date for 30th Annual NASCSA Conference Oct. 21-24, 2014

This year's **30th Annual Conference of the National Association of State Controlled Substances Authorities (NASCSA)** is now less than two months away so make your travel plans now. The conference will take place at [Hilton Savannah Desoto Hotel](#) in Savannah, Georgia October 21-24, 2014. The hotel is in close proximity to shopping and restaurants. All materials including an updated program can be accessible [here](#). Please note that the program is slightly changed from the conference brochure. Updated program materials are accessible [here](#). In the meantime, below are a few logistics:

Registration - Please make sure to submit your conference registration via email, fax or mail as soon as possible. This allows us ample time to prepare conference name badges and plan for meals/seating during the conference.

Room Rates/Hotel Information - Online reservations can be made with the hotel [here](#) or by calling the hotel directly toll-free at (877) 280-0751 (Please refer to the group code "SSA" when making reservations phone or "National Association of State Controlled Substances Authorities"). The room rate is \$140 per night single/double occupancy. The hotel features complimentary Wi-Fi access. The hotel is booking up fast so please do not delay in making your reservations as we cannot guarantee the availability of rooms/rates once the block is filled.

Ground Transportation - There are a number of transportation options available to attendees, which are listed [here](#).

Welcome Reception/luncheon - We will again be hosting a welcome dinner as well as a networking

members in providing updated information. We would ask that members periodically check their [profiles](#) to make sure they are current.

Interested in PMP Legislation?

Due to our recent collaboration with the National Alliance for Model State Drug Laws (NAMSDL), we have been provided with an updated compilation of information on state and federal legislation and regulations pertaining to Prescription Monitoring Programs as a courtesy to members. The latest listing is found [here](#) under the PMP section of our website.

State Regulatory Developments

Did you know that NASCSA publishes a monthly compilation of state regulatory actions related to pharmacy and controlled substances. State Regulatory Developments is located on the website [here](#).

Membership is Strength of NASCSA

Dues notices for the upcoming fiscal year (July 1-June 30th) have been mailed to all

luncheon that provides a unique opportunity for attendees to stay on the property and network with their colleagues.

NASCSA is "Going Green" - Once again NASCSA is "going green". Responding to the high cost of printing and shipping of conference notebooks, a smaller version of the conference materials will be provided at the conference. Presentations will be available for attendees the week prior to the conference as well as during the conference. The program, attendee list, speaker list, bylaws, resolutions, etc... will still be available in hard-copy form. This new initiative is consistent with the direction of what many other organizations are doing.

Dress Code - All meetings are "Business Casual" (we want our attendees to be comfortable, ready to learn and participate!). As temperatures in meeting rooms often are variable, we would recommend you bring a light sweater or coat to the meeting just in case. Temperatures in Savannah typically mid 70's during the day and low 50's in the evening.

Special Meeting for state PMP

Administrators/staff and Optional Session for NASCSA members - A special meeting for state PMP Administrators and an optional session for NASCSA members will take place on Tuesday, October 21, 2014 beginning at 9 a.m. A copy of the agenda is found [here](#). We encourage all to attend.

Important Reminder - Please note that the NASCSA conference will kick off at 1 p.m. on October 21, 2014 with the Business meeting. We ask **all** members to be present at this time to conduct the roll call and establish a quorum at the Business meeting.

Business Meeting - We will be including agendas for the Business meeting in the conference notebook and online. We strongly encourage all attendees to attend.

We hope to see you in October!

Travel Scholarship Winners Announced

This year saw an unprecedented number of applicants for one of six travel scholarships to attend this year's conference making it a difficult decision for the Membership Committee who was responsible for evaluating the applicants.

members. In order to be eligible to vote at the annual conference, and be eligible for travel scholarships as well as any grants awarded to states for special projects, membership dues must be paid in full.

Update Your Contact Information

if your contact information changes, please login using the original email address you originally had subscribed with and update any information including your new email address and updated contact information.

State Pain Policy Advocacy Network Resource

The State Pain Policy Advocacy Network (SPAN) offers a great resource to NASCSA members on legislation related to Prescription Drug Monitoring Programs, Pain Clinic regulations, medical marijuana (among other issues of interest). For more information visit their link [here](#).

Did You Know NASCSA is on Twitter?

If you have a Twitter account, please make

The following states/districts were selected and were approved by the Executive Committee: **Oregon, California, New Jersey, Michigan, District of Columbia** and **Pennsylvania**. Three alternates were chosen in the event a representative from one of the selected states is unable to attend. Several scholarship recipients will be attending for the first time so please introduce yourself. The Executive Committee will be discussing continuation of these popular scholarships sometime early next year.

Proposed Bylaw Changes/Resolutions to be Taken Up at the Business Meeting

The Resolutions/Bylaws Committee has been hard at work updating NASCSA's bylaws and has posted proposed changes to the bylaws along with written summary of the changes. All members are encouraged to review the proposed bylaw changes in advance of the meeting. The proposed bylaws are found [here](#).

The Committee has also been working on a number of resolutions for discussion/voting at the conference. Among the resolutions to be considered include the following:

- A resolution endorsing the model policy of the Federation of State Medical Boards on the use of Opioid Analgesics in the Treatment of Pain;
- A Resolution Suspending NASCSA Resolution 2011-05;
- A Resolution Encouraging Controlled Substance Manufacturers to Increase the Number of Abuse Deterrent Opioid Formulations Available to Treat Patients;
- A Resolution Encouraging State Healthcare Licensing Boards and Professional Healthcare Associations to Advocate Judicious Prescribing of Opioid Analgesics and Other Controlled Substances Following Medical and Dental Procedures or Upon Patient Discharge;
- A Resolution Relative to Drug Disposal;
- A Resolution Encouraging Jurisdictions to Provide Drug Diversion Training to Law Enforcement Personnel, Establish Drug Prevention Programs and Drug Diversion Investigative Units;

sure to follow us @NASCSA. Our followers are growing by leaps and bounds so spread the word and stay connected!

- A Resolution Encouraging Medical Facilities to Provide Training to all Healthcare Professionals Who have Access and/or Exposure to Controlled Substances;
- A Resolution Encouraging the Adoption of Rules/Regulations Requiring Medical Facilities to Report Employees Who Divert Controlled Substances; and
- A Resolution Supporting Good Samaritan Laws Regarding the Use of Opiate Antagonists.

Copies of the proposed regulations are found [here](#).

From the States

Montana - Marcie Bough, PharmD, Executive Director of the Montana Board of Pharmacy, recently received the FDA Commissioner's Special Citation Award. As former Senior Director of Government Affairs for the American Pharmacists Association, Marci's contributions to FDA's implementation of Risk Evaluation and Mitigation Strategies (REMS) were noted according to FFFDA Commissioner Margaret Hamburg, MD.

Kentucky - The Kentucky Office of Drug Control Policy announced it is receiving a \$1 million "Prescription Drug Overdose Prevention Boost" grant from the Centers for Disease Control (CDC) and Prevention to combat a rising prescription drug overdose death epidemic. Just five states were awarded the three-year grant, according to a news release.

West Virginia - Received [\\$1 million](#) from CDC over the next three years to strengthen its Prescription Monitoring Program and develop new drug abuse prevention strategies.

Researchers Publish Study on Unsolicited PMP Reporting

Researchers with the PDMP Center of Excellence, led by Cindy Parks Thomas, Ph.D., have published a study on sending unsolicited prescription history reports to prescribers about patients in their practices who might be doctor shopping. The study was

conducted in collaboration with staff from the Massachusetts Prescription Monitoring Program (MA PMP), MA Department of Public Health. Prescribers who received unsolicited reports from the MA PMP were asked to indicate the extent to which they knew about other prescribers for the patients and whether the prescriptions the patients received were medically necessary. Only 8.4% of respondents knew about all or nearly all the other prescribers for patients reported on, and of those who felt they had sufficient knowledge to make a judgment, nearly 70% judged that the prescriptions for these patients were unwarranted. This suggests that receiving the prescription history information added to prescribers' clinically relevant knowledge of patients. Respondents reported taking a variety of actions in response to the reports, including discussing prescription information with other providers and with patients. Most respondents felt that the reports were easy to understand and useful for their practice.

*Cindy Parks Thomas, Meelee Kim, Ruslan V. Nikitin, Peter Kreiner, Thomas W. Clark and Grant M. Carrow, "Prescriber response to unsolicited prescription drug monitoring program reports in Massachusetts," *Pharmacoepidemiology and Drug Safety*, [June 12, 2014](#).

Industry News

FDA Grants Priority Review for Single-Entity Hydrocodone Bitartrate Tablet

Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) has granted Priority Review designation for the company's once-daily, single-entity hydrocodone bitartrate tablet (HYD). This investigational pain medication was formulated to incorporate abuse-deterrent properties designed to make the product more difficult to manipulate for the purpose of misuse or abuse by various routes of administration (e.g., chewing, snorting and intravenous injection).

Priority Review is granted by the FDA to applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. Designation of a drug as "Priority" does not alter the scientific/medical standard for approval or the quality of evidence necessary. Purdue announced filing the

New Drug Application (NDA) for hydrocodone bitartrate tablet (HYD) in April 2014 and the FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of October 2014.

FDA approves new extended-release oxycodone with abuse-deterrent properties

The U.S. Food and Drug Administration recently approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting (ER/LA) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Targiniq ER is the second ER/LA opioid analgesic with FDA-approved labeling describing the product's abuse-deterrent properties consistent with the FDA's 2013 draft guidance for industry, *Abuse-Deterrent Opioids - Evaluation and Labeling*. The announcement is found [here](#).

We hope you enjoyed this latest edition of NASCSA News. We strongly encourage members and others to share information from their respective agencies for consideration for our newsletter. Please email KathyKeough@nascsa.org with your articles and ideas.

Sincerely,

Kathy Keough
Executive Director

N.A.S.C.S.A | 72 Brook Street | Quincy | MA | 02170